JP2024532845A5 - - Google Patents

Info

Publication number
JP2024532845A5
JP2024532845A5 JP2024510224A JP2024510224A JP2024532845A5 JP 2024532845 A5 JP2024532845 A5 JP 2024532845A5 JP 2024510224 A JP2024510224 A JP 2024510224A JP 2024510224 A JP2024510224 A JP 2024510224A JP 2024532845 A5 JP2024532845 A5 JP 2024532845A5
Authority
JP
Japan
Prior art keywords
group
optionally substituted
substituted
cancer
alternatively
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024510224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532845A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/112674 external-priority patent/WO2023020457A1/en
Publication of JP2024532845A publication Critical patent/JP2024532845A/ja
Publication of JP2024532845A5 publication Critical patent/JP2024532845A5/ja
Pending legal-status Critical Current

Links

JP2024510224A 2021-08-17 2022-08-16 ピリダジノンまたはピリジノン化合物、その製造方法および用途 Pending JP2024532845A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/112906 2021-08-17
CN2021112906 2021-08-17
PCT/CN2022/112674 WO2023020457A1 (en) 2021-08-17 2022-08-16 Pyridazinone or pyridinone compounds, preparation methods and uses thereof

Publications (2)

Publication Number Publication Date
JP2024532845A JP2024532845A (ja) 2024-09-10
JP2024532845A5 true JP2024532845A5 (enExample) 2025-08-13

Family

ID=85240081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024510224A Pending JP2024532845A (ja) 2021-08-17 2022-08-16 ピリダジノンまたはピリジノン化合物、その製造方法および用途

Country Status (5)

Country Link
US (1) US20240343727A1 (enExample)
EP (1) EP4387966A4 (enExample)
JP (1) JP2024532845A (enExample)
CN (1) CN117897380A (enExample)
WO (1) WO2023020457A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4423078A1 (en) * 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN119968364A (zh) * 2022-09-30 2025-05-09 阿兹卡拉疗法公司 哒嗪-3(2h)-酮和吡啶-2(1h)-酮parp抑制剂化合物
GB202217888D0 (en) * 2022-11-29 2023-01-11 Duke Street Bio Ltd Pharmaceutical compound
TW202430518A (zh) * 2023-01-06 2024-08-01 大陸商齊魯製藥有限公司 Parp7抑制劑的製備方法
CN116874496B (zh) * 2023-07-10 2025-07-25 东南大学 三环类化合物及其制备方法、药物组合物和应用
CN117777099A (zh) * 2023-12-26 2024-03-29 诺沃斯达药业(上海)有限公司 Parp7抑制剂及其用途
CN118772063B (zh) * 2024-07-04 2025-06-13 西北师范大学 一种四氢哒嗪类化合物的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
KR20070057859A (ko) * 2004-08-26 2007-06-07 쿠도스 파마슈티칼스 리미티드 4-헤테로아릴메틸 치환된 프탈라지논 유도체
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
AR070221A1 (es) * 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
CN103130723B (zh) * 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN106946792B (zh) * 2017-03-29 2019-07-26 深圳市坤健创新药物研究院 一种酞嗪酮的异羟肟酸衍生物及其制备方法与应用
EP3737361A4 (en) * 2018-01-11 2021-08-25 Centaurus Therapeutics INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR THE TREATMENT OF DISEASES
BR112020022006A2 (pt) * 2018-04-30 2021-01-26 Ribon Therapeutics Inc. piridazinonas como inibidores de parp7
CN119552152A (zh) * 2018-10-12 2025-03-04 益方生物科技(上海)股份有限公司 甲状腺激素受体激动剂
WO2021087018A1 (en) * 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药(上海)有限公司 作为parp7抑制剂的哒嗪酮类化合物

Similar Documents

Publication Publication Date Title
EP4001276B1 (en) Aurora kinase inhibitor and use thereof
JP2024530495A5 (enExample)
JP2025160318A5 (enExample)
JP2024522766A5 (enExample)
JP2024099041A5 (enExample)
JP2023520333A5 (enExample)
JP2020517616A5 (enExample)
BG64838B1 (bg) Производни на индолил-3-глиоксиловата киселина с антитуморно действие
JP2007511504A5 (enExample)
JP2021523225A5 (enExample)
JP2019519476A5 (enExample)
JP2024522174A5 (enExample)
JP2022526266A5 (enExample)
JP2016523973A5 (enExample)
JP2018524403A5 (enExample)
JP2020063289A5 (enExample)
JP2023542065A5 (enExample)
JP4897938B2 (ja) N−[6−(cis−2,6−ジメチルモルホリン−4−イル)ピリジン−3−イル]−2−メチル−4’−(トリフルオロメトキシ)[1,1’−ビフェニル]−3−カルボキサミドの塩
JP2022541747A5 (enExample)
JP2002509930A (ja) ベンゾ複素環ジスタマイシン誘導体、その製造方法および抗腫瘍薬としてのそれの使用
JP2020502116A5 (enExample)
JP2019504833A5 (enExample)
JP2007532628A5 (enExample)
BRPI0509912B1 (pt) compostos, processo para a preparação dos mesmos, composição farmacêutica, e, uso de um composto
JP2024515061A5 (enExample)